NCT07040930View on ClinicalTrials.gov

Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 5, 2026

Study Completion Date

September 20, 2026

Conditions
Rheumatoid Arthritis
Interventions
DRUG

GenSci120

a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level

DRUG

Placebo

a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level

Trial Locations (1)

200040

RECRUITING

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT07040930 - Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China. | Biotech Hunter | Biotech Hunter